The short version
- The best-controlled rhodiola fatigue trial randomised 60 adults with fatigue syndrome to 576mg a day of SHR-5 extract or placebo for 28 days, and both groups improved significantly — the extract separated from placebo only on a burnout scale and three attention measures.
- In a 2000 double-blind crossover in 56 physicians on night duty, rhodiola significantly improved tests of memory, calculation, concentration and perception speed during the first two-week period, with no side effects reported in either arm.
- The two most quoted rhodiola stress studies — 101 people over four weeks and 118 burnout outpatients over twelve weeks — were both open-label and single-arm, with improvements appearing after three days and one week respectively.
- A 2015 randomised trial of 57 people with major depression found Hamilton scale declines of 8.2 points on sertraline, 5.1 on rhodiola and 4.6 on placebo, with no statistically significant difference between groups.
- In that same trial adverse events were reported by 63.2% on sertraline, 30.0% on rhodiola and 16.7% on placebo.
Fifty-six young doctors in Yerevan, working night shifts, sat a battery of tests measuring short-term memory, calculation, concentration and speed of perception — before their shift and after it, across three two-week blocks. One block they took a standardised rhizome extract. One block was washout. One block was placebo. Neither they nor the researchers knew which was which.
That is Darbinyan and colleagues, published in Phytomedicine in 2000, and it is where the modern case for this plant starts. The treatment group improved significantly on those tests during the first two-week period. No side effects were reported in either arm. The authors' own summary is deliberately narrow: the extract can reduce general fatigue under certain stressful conditions.
Hold on to that phrasing, because almost everything sold on the strength of it says something much larger.
The one properly controlled fatigue trial
Olsson and colleagues ran the phase III version in Planta Medica in 2009. Sixty adults aged 20 to 55, selected against the Swedish National Board of Health and Welfare criteria for fatigue syndrome, randomised to four tablets a day of the SHR-5 extract — 576mg a day — or four placebo tablets, for 28 days.
Here is the part that gets left out. Both groups improved significantly on the burnout scale, on the mental health component of the SF-36, on the depression rating scale, and on several attention indices. Both groups. The paper labels that plainly as a placebo effect. What separated the arms was narrower: the burnout scale, and three specific attention measures — omissions, reaction-time variability, and consistency of responding on a continuous performance test. Cortisol response to awakening also changed differently between the groups.
So the controlled signal for rhodiola is about concentration under load. Not calm, not mood, not energy in the way the word gets used on a label. Attention, in people who were already running on empty. That is a real finding and it is a small one, and it sits closer to what happens with l-theanine than to anything hormonal.
Then there are the studies without a control group
The numbers that make it into marketing come from somewhere else. Edwards and colleagues, 2012: 101 people with life-stress symptoms, 200mg twice daily for four weeks, multicentre, non-randomised, open-label, single-arm. Every one of seven questionnaires improved. Improvements appeared, the paper notes, after three days.
Kasper and Dienel, 2017: 118 outpatients with burnout symptoms, 400mg a day for twelve weeks. Also open-label. Also single-arm. The majority of outcome measures improved, several of them within the first week. The second author's listed affiliation is the pharmaceutical company that makes the extract.
Neither paper is dishonest. Both describe themselves accurately as exploratory, and Kasper's stated purpose was to generate hypotheses for future randomised trials. The problem is downstream: those are the trials that get quoted, because those are the trials where everything worked. In a design where every participant knows they are being treated and there is nothing to compare against, improvement after three days is not evidence about the plant. Olsson's placebo group told you that already.
The head-to-head nobody talks about
Mao and colleagues, in Phytomedicine in 2015, randomised 57 people with mild to moderate major depression to twelve weeks of standardised rhodiola extract, sertraline, or placebo. All three groups showed modest reductions on the Hamilton and Beck scales. None of the differences between groups reached significance. The decline on the Hamilton scale was 8.2 points for sertraline, 5.1 for rhodiola and 4.6 for placebo.
What did separate was tolerability: adverse events were reported by 63.2% on sertraline, 30.0% on rhodiola and 16.7% on placebo. A proof-of-concept trial in 57 people is too small to call anything equivalent, and the authors do not. But it is the closest thing to a fair fight this plant has had, and rhodiola did not win it.
What we'd actually tell you
We do not sell rhodiola, so take this as freely as it is given. If you want to try it, the doses with controlled data behind them are roughly 400 to 576mg a day of a standardised root extract, and the outcome to watch is whether you can hold your attention on something difficult late in a hard day. Judge it at four weeks, which is how long the controlled trials ran. Not three days.
If what you are actually describing is burnout rather than fatigue, no extract addresses the thing generating it, and the trials that appear to say otherwise are the uncontrolled ones. And if you are wondering whether you would need to cycle adaptogens like this one, the answer is that nobody has tested that either — in this plant's case, nobody has tested continuous use past twelve weeks at all.
Good questions
What dose of rhodiola do the studies actually use?
Between roughly 400 and 576mg a day of a standardised root extract in the trials with control groups. The night-duty crossover used a repeated low-dose regimen of one tablet daily. Doses far below that range have not been compared against placebo for fatigue, so a smaller capsule is an untested intervention rather than a gentler version of a tested one.
Does rhodiola give you energy?
Not in the way the word is used on a label. The controlled findings are about attention — fewer lapses, steadier reaction times, holding concentration late in a demanding shift. Nobody has shown it raises subjective energy against placebo in rested people. If you are looking for a stimulant effect, this is not the mechanism that has been demonstrated.
How long before rhodiola does anything?
Judge it at four weeks. That is the length of the properly controlled fatigue trial. Reports of improvement within three days come from open-label studies with no comparison group, where the expectation of treatment is doing work you cannot separate from the extract. Four weeks is also long enough for the novelty of a new routine to wear off.
Is rhodiola as good as an antidepressant?
No, and the one trial that compared them directly should not be read that way. In 57 people over twelve weeks, sertraline produced a larger Hamilton scale decline than rhodiola, and neither beat placebo significantly. A study that small cannot demonstrate equivalence. If you are on a prescription for depression, this is not a substitution to make on your own.
Why don't you sell rhodiola if it has trials behind it?
Because the controlled evidence supports one narrow claim — attention under sustained load — and the market for it is built on a much broader one. We would rather point you at the four studies than build a product page around the two uncontrolled ones. If that changes when someone runs a larger blinded trial, we will say so.
Sources
- Darbinyan V, Kteyan A, Panossian A, et al. Rhodiola rosea in stress induced fatigue--a double blind cross-over study of a standardized extract SHR-5 with a repeated low-dose regimen on the mental performance of healthy physicians during night duty. Phytomedicine, 2000. View study
- Olsson EM, von Schéele B, Panossian AG. A randomised, double-blind, placebo-controlled, parallel-group study of the standardised extract SHR-5 of the roots of Rhodiola rosea in the treatment of subjects with stress-related fatigue. Planta Med, 2009. View study
- Edwards D, Heufelder A, Zimmermann A. Therapeutic effects and safety of Rhodiola rosea extract WS 1375 in subjects with life-stress symptoms--results of an open-label study. Phytother Res, 2012. View study
- Kasper S, Dienel A. Multicenter, open-label, exploratory clinical trial with Rhodiola rosea extract in patients suffering from burnout symptoms. Neuropsychiatr Dis Treat, 2017. View study
- Mao JJ, Xie SX, Zee J, et al. Rhodiola rosea versus sertraline for major depressive disorder: A randomized placebo-controlled trial. Phytomedicine, 2015. View study
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
